Evidence map›Paper›PMID 34446030›Full record

ArticleWorld journal of surgical oncology2021

Higher titer hepatitis B core antibody predicts a higher risk of liver metastases and worse survival in patients with colorectal cancer.

Ziyao Li, Shaofei Li, Hangbo Tao, Yixiang Zhan, Kemin Ni, Jianfeng Gong, Guoxun Li

Open access · greenAbstract read
In one paragraph

Article in World journal of surgical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Ziyao LiDepartment of Colorectal Surgery, Tianjin Union Medical Center, No. 190 Jieyuan street, Hongqiao District, Tianjin, 300121, China.
Shaofei LiDepartment of Colorectal Surgery, Tianjin Union Medical Center, No. 190 Jieyuan street, Hongqiao District, Tianjin, 300121, China.
Hangbo TaoDepartment of Colorectal Surgery, Tianjin Union Medical Center, No. 190 Jieyuan street, Hongqiao District, Tianjin, 300121, China.
Yixiang ZhanDepartment of Colorectal Surgery, Tianjin Union Medical Center, No. 190 Jieyuan street, Hongqiao District, Tianjin, 300121, China.
Kemin NiDepartment of Colorectal Surgery, Tianjin Union Medical Center, No. 190 Jieyuan street, Hongqiao District, Tianjin, 300121, China.
Jianfeng GongDepartment of General Surgery, Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
Guoxun LiDepartment of Colorectal Surgery, Tianjin Union Medical Center, No. 190 Jieyuan street, Hongqiao District, Tianjin, 300121, China. liguoxun6@163.com.ORCID http://orcid.org/0000-0003-4869-5713
Tianjin People's Hospital · CNNanjing General Hospital of Nanjing Military Command · CN

Funding

Major Research Plan 81970469
6 · The paper itself

Abstract

backgroundThere have been controversial voices on if hepatitis B virus infection decreases the risk of colorectal liver metastases or not. This study aims to the find the association between HBV infection and postoperative survival of colorectal cancer and the risk of liver metastases in colorectal cancer patients.

methodsPatients who underwent curative surgical resection for colorectal cancer between January 2011 and December 2012 were included. Patients were grouped according to anti-HBc. Differences in overall survival, time to progress, and hepatic metastasis-free survival between groups and significant predictors were analyzed.

resultsThree hundred twenty-seven colorectal cancer patients were comprised of 202 anti-HBc negative cases and 125 anti-HBc positive cases, and anti-HBc positive cases were further divided into high-titer anti-HBc group (39) and low-titer anti-HBc group (86). The high-titer anti-HBc group had significantly worse overall survival (5-Yr, 65.45% vs. 80.06%; P < .001), time to progress (5-Yr, 44.26% vs. 84.73%; P < .001), and hepatic metastasis-free survival (5-Yr, 82.44% vs. 94.58%; P = .029) than the low-titer group. Multivariate model showed anti-HBc ≥ 8.8 S/CO was correlated with poor overall survival (HR, 3.510; 95% CI, 1.718-7.17; P < .001), time to progress (HR, 5.747; 95% CI, 2.789-11.842; P < .001), and hepatic metastasis-free survival (HR, 3.754; 95% CI, 1.054-13.369; P = .041) in the anti-HBc positive cases.

conclusionsHigher titer anti-HBc predicts a potential higher risk of liver metastases and a worse survival in anti-HBc positive colorectal cancer patients.

Indexed as

Colorectal NeoplasmsHepatitis BLiver NeoplasmsHepatitis B Core AntigensHepatitis B virusHumansPrognosisHepatitis B Core AntigensColorectal cancerColorectal liver metastasesHepatitis B core antibodyHepatitis B virus

Identifiers

PMID34446030
PMCPMC8394189
OpenAlexW3151554382

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.